Henry Schein develops rapid antibody blood test for COVID-19

By LabPulse.com staff writers

March 26, 2020 -- New York-based healthcare distribution company Henry Schein has developed a rapid blood test to help medical professionals with the diagnosis of COVID-19.

The company's Standard Q COVID-19 immunoglobulin M and G (IgM/IgG) rapid test is an immunochromatography test that can identify COVID-19 antibodies from blood drawn with a pinprick. The test provides results within 15 minutes and can be administered at the point of care.

Because of its detection of antibodies, the test can identify people with past infection, as well as those in the mid-to-late stages of the disease. Henry Schein cautioned that physicians should also consider follow-up molecular tests to confirm or rule out COVID-19.

Henry Schein is working with SD Biosensor to manufacture the tests. The company expects to have several hundred thousand tests available by March 30, with even more tests available in April.

Quest expands coronavirus testing capacity
Quest Diagnostics has ramped up the number of tests for the novel coronavirus that it is performing per day to 25,000, with diagnostics performed at 12...
T2 adds coronavirus test to panels, per health network deal
T2 Biosystems has signed a worldwide licensing agreement for a rapid test developed by New Jersey-based Hackensack Meridian Health for SARS-CoV-2.
Cepheid set to start shipping 45-minute coronavirus POC test
Danaher's Cepheid is set to start shipping a new ultrafast molecular point-of-care (POC) test soon for the novel coronavirus, after securing an emergency...

Copyright © 2020 LabPulse.com

Last Updated np 3/26/2020 1:31:31 PM